ClinicalTrials.gg
CompletedNCT04346108Updated Mar 22, 2024Results posted

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

A Phase 3 interventional study of Immune Globulin Intravenous (IGIV) and Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%) in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 8 sites in Japan. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
24th of 26
17 · median 45
Started
2020
the only one that year
Phase 3
18 of 27
2 open now
Registered
23rd of 27
by date
Lead sponsor
8 of 27
Baxalta now part of Shire

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 24th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2020, is one of 18 in phase 3, and was the 23rd registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

In this study, Japanese participants with primary immunodeficiency diseases were treated with Immune Globulin Subcutaneous (Human), 20% solution, (IGSC, 20%). This study will be in 3 parts:

Part 1: Infusions with Immunoglobulin Intravenous (IGIV) every 3 or 4 weeks for 13 weeks.

Part 2: Participants will switch to weekly subcutaneous infusions with IGSC, 20% for 24 weeks.

Part 3: A subset will receive biweekly subcutaneous infusions with IGSC, 20% for 12 weeks.

The main aim of the study is to assess base levels of Immunoglobulin globulin G (IgG) levels in the blood of the participants after weekly and biweekly treatment with IGSC, 20% (in Parts 2 and 3 of the study). Their PID will be treated by their doctor according to their doctor's usual clinical practice.

Read the detailed description

This study consists of 3 treatment parts (Epoch 1, 2, 3). The total evaluation period of the study will be 57 weeks in which screening period is for 2-8 weeks and Epoch 1 is from Week 8 to Week 21, Epoch 2 is from Week 21 to Week 45, Epoch 3 is from Week 45 to Week 57.

Each participant will receive IGIV treatment in Epoch 1 for a total of 13 weeks, then switch to weekly subcutaneous (SC) treatment with IGSC, 20% in Epoch 2 for a total of 24 weeks and will continue into Epoch 3 for a total of 12 weeks of biweekly SC treatment with IGSC, 20%. Drug dose in Epoch 2 and Epoch 3 will be adjusted so that it will be an equivalent weekly dose of the dose administered in Epoch 1 and twice the dose administrated in Epoch 2 respectively. Epoch 2 will contain two periods, period 1: dose adjustment period (first 12 weeks) and period 2: evaluation period (second 12 weeks).

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be of Japanese descent, defined as born in Japan and having Japanese parents and Japanese maternal and paternal grandparents.
  • Participants must have a documented diagnosis of a form of primary humoral immunodeficiency involving antibody formation and requiring gammaglobulin replacement. The diagnosis must be confirmed by the medical director prior to treatment with IGIV.
  • Participant is 2 years or older at the time of screening.
  • Written is obtained from either the participants or the participants legally authorized representative prior to any study-related procedures and study product administration.
  • Participant has been receiving a consistent dose of IGIV over a period of at least 3 months prior to screening equivalent to approximately 200-600 mg/kg-body weight (BW) per 3- 4 week period, as according to the product package insert
  • Participant has a serum trough level of IgG >= 5 gram per liter (g/L) at screening.
  • Participant has not had a serious bacterial infection within the 3 months prior to screening.
  • Participant is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  • Participant has a known history of or is positive at screening for one or more of the following: surface antigen (HBsAg), polymerase chain reaction (PCR) for virus (HCV), PCR for (HIV) Type 1/2.
  • Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):

    • Persistent (ALT) and aspartate amino transferase (AST) > 2.5 times the (ULN) for the testing laboratory
    • Persistent severe neutropenia (defined as an [ANC] \<= 500/milli cubic meter [mm\^3]).
  • Participant has presence of renal function impairment defined by estimated (eGFR) is \<60 milliliter per minute/ 1.73 square meter (mL/min/1.73m\^2).
  • Participant has been diagnosed with or has a (other than adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix), unless the disease-free period prior to screening exceeds 5 years.
  • Participant is receiving anti-coagulation therapy or has a history of thrombotic episodes (including deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism) within 12 months prior to screening or a history of thrombophilia.
  • Participant has abnormal protein loss (protein losing enteropathy, nephrotic syndrome).
  • Participant has anemia that would preclude phlebotomy for laboratory studies according to standard practice at the site.
  • Participant has an ongoing history of or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IV immunoglobulin, SC immunoglobulin, and/or Immune Serum Globulin (ISG) infusions.
  • Participant has immunoglobulin A (IgA) deficiency (IgA less than 0.07 g/L), known anti IgA antibodies, and a history of hypersensitivity.
  • Participant is on preventative (prophylactic) systemic antibacterial antibiotics at doses sufficient to treat or prevent bacterial infections, and cannot stop these antibiotics at the time of screening.
  • Participant has active infection and is receiving antibiotic therapy for the treatment of infection at the time of screening.
  • Participant has a bleeding disorder, or a count less than 20,000/ microliter (mcL), or, in the opinion of the investigator, would be at significant risk of increased bleeding or bruising as a result of subcutaneous therapy.
  • Participant has total protein > 9 gram per deciliter (g/dL) or myeloma, or macroglobulinemia (IgM) or paraproteinemia.
  • Women of meeting any one of the following criteria:

    • Participant presents with a positive pregnancy test.
    • Participant is breast feeding.
    • Participant intends to begin nursing during the course of the study.
    • Participant does not agree to employ adequate birth-control measures (e.g. intrauterine device, diaphragm or condom [for male partner] with spermicidal jelly or foam, or pills/patches) throughout the course of the study.
  • Participant has participated in another clinical study and has been exposed to an IP or device within 30 days prior to study enrollment.
  • Participant is scheduled to participate in another non-observational (interventional) clinical study involving an IP or device during the course of the study.
  • Participant has severe dermatitis that would preclude adequate sites for safe product administration.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Epoch 1: IGIV 200-600 mg/kg

    Participants received 200 to 600 mg/kg of Immunoglobulin Intravenous (IGIV) infusion for every 3 or 4 weeks for up to 13 weeks.

    Biological: Immune Globulin Intravenous (IGIV)

  • Experimental
    Epoch 2: IGSC (20%) 50-200 mg/kg

    Participants who entered to Epoch 2 from Epoch 1 received 50-200 mg/kg of Immune Globulin Subcutaneous (Human) 20% infusion once a week up to approximately 24 weeks after Epoch 1.

    Biological: Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)

  • Experimental
    Epoch 3: IGSC (20%) 100-400 mg/kg

    Participants who entered to Epoch 3 from Epoch 1 received 100-400 mg/kg of Immune Globulin Subcutaneous (Human) 20% infusion biweekly up to approximately 12 weeks after Epoch 2.

    Biological: Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)

Interventions

  • Participants will receive IGIV infusion.

    Also known as: Immune Globulin Infusion (Human)

  • BiologicalImmune Globulin Subcutaneous, 20% Solution (IGSC, 20%)

    Drug pages: Immunoglobulins · Solutions

    Participants will receive IGSC, 20% SC infusion.

    Also known as: Immune Globulin Infusion (Human)

06

What researchers measure

Primary outcomes

  1. Epoch 2: Total Serum Trough Levels of Immune Globulin G (IgG) Antibodies During Period 2

    Total serum trough levels of IgG antibodies measured during period 2 of Epoch 2 were assessed.

    Time frame: Epoch 2 (period 2): Up to 24 weeks

  2. Epoch 3: Total Serum Trough Levels of IgG Antibodies

    Total serum trough levels of IgG antibodies measured during Epoch 3 were assessed.

    Time frame: Epoch 3: Up to Week 12

Secondary outcomes

  1. Epoch 1: Total Serum Trough Levels of IgG Antibodies

    Total serum trough levels of IgG antibodies measured during Epoch 1 were assessed.

    Time frame: Epoch 1: Up to Week 13

  2. Epoch 2: Area Under the Curve From Time 0 to Last Interval (AUC0-last) for Total Serum Levels of IgG

    Time frame: Epoch 2: Week 21

  3. Epoch 2: AUC0-last for Total Serum Levels of IgG Subclasses

    Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.

    Time frame: Epoch 2: Week 21

  4. Epoch 2: Apparent Clearance (CL/F) for Total Serum Levels of IgG

    Time frame: Epoch 2: Week 21

  5. Epoch 2: CL/F for Total Serum Levels of IgG Subclasses

    Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.

    Time frame: Epoch 2: Week 21

  6. Epoch 2: Maximum Concentration (Cmax) for Total Serum Levels of IgG

    Time frame: Epoch 2: Week 21

  7. Epoch 2: Cmax for Total Serum Levels of IgG Subclasses

    Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.

    Time frame: Epoch 2: Week 21

  8. Epoch 2: Minimum Concentration (Cmin) for Total Serum Levels of IgG

    Time frame: Epoch 2: Week 21

  9. Epoch 2: Cmin for Total Serum Levels of IgG Subclasses

    Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.

    Time frame: Epoch 2: Week 21

  10. Epoch 2: Time to Maximum Concentration (Tmax) for Total Serum Levels of IgG

    Time frame: Epoch 2: Week 21

  11. Epoch 2: Tmax for Total Serum Levels of IgG Subclasses

    Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.

    Time frame: Epoch 2: Week 21

  12. Trough Levels of Specific Antibodies to Clinically Relevant Pathogens: Clostridium Tetani Toxoid and Hepatitis B Virus (HBV)

    Trough levels of specific antibodies to clinically relevant pathogen (Clostridium tetani toxoid and HBV) were assessed in Epoch 1, Epoch 2 and Epoch 3. Data was analyzed per interval in each Epoch for this outcome measure.

    Time frame: Epoch 1 (Week 1); Epoch 2 (Week 1, 24); Epoch 3 (Week 1, 13)

  13. Trough Levels of Specific Antibodies to Clinically Relevant Pathogen: Haemophilus Influenzae (HIB)

    Trough levels of specific antibodies to clinically relevant pathogens (HIB) were assessed in Epoch 1, Epoch 2, and Epoch 3. Data was analyzed per interval in each Epoch for this outcome measure.

    Time frame: Epoch 1 (Week 1); Epoch 2 (Week 1, 24); Epoch 3 (Week 1, 13)

  14. Health Related Quality of Life: Treatment Preference

    Treatment preference questionnaire is a self-administered questionnaire developed to assess participants' preference towards the administration of new IGSC therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment. The questionnaire included following categories: Where do you prefer to receive your immunoglobulin therapy, The frequency of administration, as pre-specified in protocol, data is reported as per age (2-13 years and \>=14 years).

    Time frame: Up to approximately 1.5 years

  15. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAEs was defined as adverse events (AEs) with onset after date-time of first dose of study drug, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Any TEAE that is recorded by the investigator as "possibly related" or "probably related" to IP was considered as IGSC, 20%-related AE, and any AE recorded as "unlikely related" or "not related" was considered as unrelated AE. AEs included vital signs, clinical laboratory measurements.

    Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)

  16. Number of Participants With Tolerability Events Related to the Infusion of Study Drug

    An infusion is considered tolerable if the infusion rate was not reduced, or the infusion was not interrupted or stopped, due to TEAE related to study drug (IGIV or IGSC) infusion. A tolerability event is considered to have occurred if an infusion was not tolerable in Epoch 1, Epoch 2 and Epoch 3. Number of participants with tolerability events related to infusion of IP were assessed.

    Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)

  17. Annual Rate of Validated Acute Serious Bacterial Infections (ASBI)

    The ASBI rate was calculated as the mean number of acute serious bacterial infections per participants per year. Annual rate of validated acute serious bacterial infections per participant was assessed.

    Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)

  18. Annual Rate of All Infections Per Year

    Annual rate is the number of participants reporting any infection per year.

    Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)

  19. Number of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection

    Number of days not able to attend school or work to perform normal daily activities due to illness/infection are standardized per year (365.25 days). The number of days not able to attend school or work to perform normal daily activities due to illness/infection were assessed.

    Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)

  20. Number of Days Participants Were on Antibiotics

    Number of days on antibiotics is defined as the number of days those antibiotics were taken as concomitant medications and is standardized to per year (365.25 days). Antibiotics are defined as any medication under anatomical therapeutic chemical Level 2 therapeutic class "ANTIBACTERIALS FOR SYSTEMIC USE". If a participant took multiple antibiotics on a single day, that day is counted for only once. Protocol defined prophylactic antibiotics for viral, fungal or protozoal infections (e.g. trimethoprim/sulfamethoxazole twice a week for pneumocystis) which are not treated by immunoglobulin, were excluded from this analysis.

    Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)

  21. Number of Participants Hospitalized Due to Illness or Infection

    Number of participants with hospitalization are standardized to per year (365.25 days). A hospitalization is counted for a specific epoch only if that hospitalization started during that epoch.

    Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)

  22. Length of Hospital Stay

    Length of hospital stay per stay is standardized to per year (365.25 days). A hospitalization is counted for a specific epoch only if that hospitalization started during that epoch.

    Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)

  23. Number of Acute Physician Visits Due to Illness/Infection

    Number of acute physician visits is standardized to per year (365.25 days).

    Time frame: From first dose of study drug up to end of study (up to approximately 1.5 years)

  24. Health-related Quality of Life (HRQoL): Pediatric Quality of Life Inventory (PedsQL) Total Scale Score

    Peds-QL=generic HR QoL instrument designed specifically for pediatrics has domains as:general health/activities,feelings/emotional,social functioning,school functioning.In this study,2-7 years (parent as observer),8-13 years (participant as observer) for Peds-QL health questionnaire was analyzed.Higher scores=better QOL for all domains.This modular instrument used 5-point scale:0(never) to 4(almost always).Items are reversed scored;linearly transformed to 0-100 scale as follows:0=100,1=75,2=50,3=25,4=0.4 dimensions(physical, emotional, social, \& school functioning) are scored.PEDS-QL Total Scale Score has 0-100 scale,higher scores=better HRQoL.

    Time frame: Baseline up to end of study (approximately 1.5 years)

  25. EuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Total Scale Score

    EQ-5D-3L health questionnaire=participant answered questionnaire scoring 5 dimensions -mobility,self-care,usual activities, pain/discomfort and anxiety/depression. n this study, 2-11 years (parent as observer),12 years and older (participant as observer) for EQ-5D-3L health questionnaire was analyzed.Health state index score range from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.EQ visual analogue scale range from 0 to 100, where higher scores indicate better health status.Data is reported as per age groups (2-11 years and \>=12 years).

    Time frame: Baseline up to end of the study (approximately 1.5 years)

  26. Health-related Quality of Life (HRQoL): Short Form-36 Health Survey (SF-36) Score

    SF-36=generic quality-of-life instrument that has been widely used to assess HRQL of participants.In this study, 14 years and older (participant as observer) for SF-36 health questionnaire was analyzed. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases.SF-36=36 items aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100.Higher scores=better HRQL. As pre-specified in protocol data is reported for participants with age group of 14 years or older.

    Time frame: Baseline up to end of the study (approximately 1.5 years)

  27. Health Related Quality of Life: Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) Score

    TSQM=is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. In this study, 2-12 years (parent as observer), 13 years and older (participant as observer) for TSQM health questionnaire will be analyzed. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain. As pre-specified in protocol, data is reported as per age group (2-12 years and \>=13 years).

    Time frame: Baseline up to end of the study (approximately 1.5 years)

  28. Health Related Quality of Life: Treatment Satisfaction Questionnaire for Life Quality Index (LQI) Score

    LQI=self-administered questionnaire developed specifically for participants/legal guardians involved in IGIV treatments.2-13 years (parent as observer),14 years and older (participant as observer) for LQI health questionnaire was analyzed.LQI=15-items, divided into 4 domains: treatment interferences(TI)\[6 items\],therapy-related problems(TRP)\[4 items\],therapy setting(TS)\[3 items\];treatment costs(TC)\[2 items\].Items are rated on a 7-point Likert-type scale ranging from 1:"Extremely bad" to 7:"Extremely good".Total scores=0 to 100,higher scores=highest possible satisfaction with factors such as independence,therapy convenience,social/school/work activities;health and travel costs.As pre-specified in protocol, data is reported as per age (2-13 years and \>=14 years).All-Treated Set included all enrolled participants of age group '2-13 years' and '\>=14 years' who received at least 1 dose of study drug (IGIV or IGSC).'n'=Number analysed are participants with data available for analysis.

    Time frame: Baseline up to end of the study (approximately 1.5 years)

07

Results

Posted Mar 22, 2024

Participant flow

Participants took part in the study at 8 investigative sites in Japan from 11 August 2020 to 22 December 2021.

Epoch 1 (13 Weeks)
Participant flow — Epoch 1 (13 Weeks)
MilestoneEpoch 1: IGIV 200-600 mg/kgEpoch 2: IGSC (20%) 50-200 mg/kgEpoch 3: IGSC (20%) 100-400 mg/kg
Started1700
Completed1700
Not completed000
Epoch 2 (24 Weeks After Epoch 1)
Participant flow — Epoch 2 (24 Weeks After Epoch 1)
MilestoneEpoch 1: IGIV 200-600 mg/kgEpoch 2: IGSC (20%) 50-200 mg/kgEpoch 3: IGSC (20%) 100-400 mg/kg
Started0170
Completed0150
Not completed020
Withdrew: Withdrawal by parent/guardian010
Withdrew: Withdrawal by subject010
Epoch 3 (12 Weeks After Epoch 2)
Participant flow — Epoch 3 (12 Weeks After Epoch 2)
MilestoneEpoch 1: IGIV 200-600 mg/kgEpoch 2: IGSC (20%) 50-200 mg/kgEpoch 3: IGSC (20%) 100-400 mg/kg
Started007
Completed007
Not completed000

Outcome measures

PrimaryEpoch 2: Total Serum Trough Levels of Immune Globulin G (IgG) Antibodies During Period 2

Total serum trough levels of IgG antibodies measured during period 2 of Epoch 2 were assessed.

Time frame:
Epoch 2 (period 2): Up to 24 weeks
Reported as:
Geometric mean · grams per liter (g/L)
Epoch 2: Total Serum Trough Levels of Immune Globulin G (IgG) Antibodies During Period 2
grams per liter (g/L)Epoch 2: IGSC (20%) 50-200 mg/kg
Epoch 2: Total Serum Trough Levels of Immune Globulin G (IgG) Antibodies During Period 28.56 (8.03 to 9.12)
PrimaryEpoch 3: Total Serum Trough Levels of IgG Antibodies

Total serum trough levels of IgG antibodies measured during Epoch 3 were assessed.

Time frame:
Epoch 3: Up to Week 12
Reported as:
Geometric mean · g/L
Epoch 3: Total Serum Trough Levels of IgG Antibodies
g/LEpoch 3: IGSC (20%) 100-400 mg/kg
Epoch 3: Total Serum Trough Levels of IgG Antibodies8.39 (7.89 to 8.91)
SecondaryEpoch 1: Total Serum Trough Levels of IgG Antibodies

Total serum trough levels of IgG antibodies measured during Epoch 1 were assessed.

Time frame:
Epoch 1: Up to Week 13
Reported as:
Geometric mean · g/L
Epoch 1: Total Serum Trough Levels of IgG Antibodies
g/LEpoch 1: IGIV 200-600 mg/kg
Epoch 1: Total Serum Trough Levels of IgG Antibodies8.18 (7.71 to 8.68)
SecondaryEpoch 2: Area Under the Curve From Time 0 to Last Interval (AUC0-last) for Total Serum Levels of IgG
Time frame:
Epoch 2: Week 21
Reported as:
Geometric mean · g*day/L
Epoch 2: Area Under the Curve From Time 0 to Last Interval (AUC0-last) for Total Serum Levels of IgG
g*day/LEpoch 2: IGSC (20%) 50-200 mg/kg
Epoch 2: Area Under the Curve From Time 0 to Last Interval (AUC0-last) for Total Serum Levels of IgG58.9 (48.7 to 71.3)
SecondaryEpoch 2: AUC0-last for Total Serum Levels of IgG Subclasses

Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.

Time frame:
Epoch 2: Week 21
Reported as:
Geometric mean · g*day/L
Epoch 2: AUC0-last for Total Serum Levels of IgG Subclasses
g*day/LEpoch 2: IGSC (20%) 50-200 mg/kg
IgG 135.8 (32.4 to 39.5)
IgG 223.4 (20.4 to 26.9)
IgG 31.32 (0.624 to 2.80)
IgG 41.67 (1.10 to 2.53)
SecondaryEpoch 2: Apparent Clearance (CL/F) for Total Serum Levels of IgG
Time frame:
Epoch 2: Week 21
Reported as:
Geometric mean · mL/kg/day
Epoch 2: Apparent Clearance (CL/F) for Total Serum Levels of IgG
mL/kg/dayEpoch 2: IGSC (20%) 50-200 mg/kg
Epoch 2: Apparent Clearance (CL/F) for Total Serum Levels of IgG1.93 (1.71 to 2.19)
SecondaryEpoch 2: CL/F for Total Serum Levels of IgG Subclasses

Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.

Time frame:
Epoch 2: Week 21
Reported as:
Geometric mean · mL/kg/day
Epoch 2: CL/F for Total Serum Levels of IgG Subclasses
mL/kg/dayEpoch 2: IGSC (20%) 50-200 mg/kg
IgG 13.18 (2.88 to 3.51)
IgG 24.86 (4.18 to 5.66)
IgG 399.5 (37.1 to 266)
IgG 468.3 (48.3 to 96.6)
SecondaryEpoch 2: Maximum Concentration (Cmax) for Total Serum Levels of IgG
Time frame:
Epoch 2: Week 21
Reported as:
Geometric mean · g/L
Epoch 2: Maximum Concentration (Cmax) for Total Serum Levels of IgG
g/LEpoch 2: IGSC (20%) 50-200 mg/kg
Epoch 2: Maximum Concentration (Cmax) for Total Serum Levels of IgG9.08 (7.46 to 11.1)
SecondaryEpoch 2: Cmax for Total Serum Levels of IgG Subclasses

Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.

Time frame:
Epoch 2: Week 21
Reported as:
Geometric mean · g/L
Epoch 2: Cmax for Total Serum Levels of IgG Subclasses
g/LEpoch 2: IGSC (20%) 50-200 mg/kg
IgG 15.40 (4.95 to 5.89)
IgG 23.51 (3.06 to 4.03)
IgG 30.202 (0.0960 to 0.425)
IgG 40.256 (0.169 to 0.387)
SecondaryEpoch 2: Minimum Concentration (Cmin) for Total Serum Levels of IgG
Time frame:
Epoch 2: Week 21
Reported as:
Geometric mean · g/L
Epoch 2: Minimum Concentration (Cmin) for Total Serum Levels of IgG
g/LEpoch 2: IGSC (20%) 50-200 mg/kg
Epoch 2: Minimum Concentration (Cmin) for Total Serum Levels of IgG7.45 (6.17 to 8.99)
SecondaryEpoch 2: Cmin for Total Serum Levels of IgG Subclasses

Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.

Time frame:
Epoch 2: Week 21
Reported as:
Geometric mean · g/L
Epoch 2: Cmin for Total Serum Levels of IgG Subclasses
g/LEpoch 2: IGSC (20%) 50-200 mg/kg
IgG 14.89 (4.34 to 5.51)
IgG 23.15 (2.70 to 3.68)
IgG 30.181 (0.0861 to 0.381)
IgG 40.218 (0.153 to 0.311)
SecondaryEpoch 2: Time to Maximum Concentration (Tmax) for Total Serum Levels of IgG
Time frame:
Epoch 2: Week 21
Reported as:
Median · hours
Epoch 2: Time to Maximum Concentration (Tmax) for Total Serum Levels of IgG
hoursEpoch 2: IGSC (20%) 50-200 mg/kg
Epoch 2: Time to Maximum Concentration (Tmax) for Total Serum Levels of IgG71.08 (22.82 to 168.23)
SecondaryEpoch 2: Tmax for Total Serum Levels of IgG Subclasses

Total serum levels of IgG subclasses IgG 1, IgG 2, IgG 3, and IgG 4 were determined.

Time frame:
Epoch 2: Week 21
Reported as:
Median · hours
Epoch 2: Tmax for Total Serum Levels of IgG Subclasses
hoursEpoch 2: IGSC (20%) 50-200 mg/kg
IgG 171.08 (22.82 to 118.80)
IgG 271.08 (0.00 to 164.32)
IgG 372.92 (71.08 to 118.80)
IgG 471.17 (70.13 to 118.80)
SecondaryTrough Levels of Specific Antibodies to Clinically Relevant Pathogens: Clostridium Tetani Toxoid and Hepatitis B Virus (HBV)

Trough levels of specific antibodies to clinically relevant pathogen (Clostridium tetani toxoid and HBV) were assessed in Epoch 1, Epoch 2 and Epoch 3. Data was analyzed per interval in each Epoch for this outcome measure.

Time frame:
Epoch 1 (Week 1); Epoch 2 (Week 1, 24); Epoch 3 (Week 1, 13)
Reported as:
Geometric mean · International units (IU)/mL
Trough Levels of Specific Antibodies to Clinically Relevant Pathogens: Clostridium Tetani Toxoid and Hepatitis B Virus (HBV)
International units (IU)/mLEpoch 1: IGIV 3-week Interval (Week 1)Epoch 1: IGIV 4-week Interval (Week 1)Epoch 2: IGSC, 20% Weekly (Week 1)Epoch 2: IGSC, 20% Weekly (EOS [Week 24]/ET)Epoch 3: IGSC, 20% Biweekly (Week 1)Epoch 3: IGSC, 20% Biweekly (Week 13)
Clostridium Tetani Toxoid0.524 (0.290 to 0.949)0.602 (0.364 to 0.997)0.674 (0.468 to 0.970)1.52 (1.11 to 2.08)1.97 (1.65 to 2.35)1.80 (1.35 to 2.39)
Hepatitis B Virus27.7 (17.8 to 43.0)35.2 (17.5 to 70.9)54.1 (33.7 to 87.0)486 (335 to 706)645 (452 to 920)923 (832 to 1020)
SecondaryTrough Levels of Specific Antibodies to Clinically Relevant Pathogen: Haemophilus Influenzae (HIB)

Trough levels of specific antibodies to clinically relevant pathogens (HIB) were assessed in Epoch 1, Epoch 2, and Epoch 3. Data was analyzed per interval in each Epoch for this outcome measure.

Time frame:
Epoch 1 (Week 1); Epoch 2 (Week 1, 24); Epoch 3 (Week 1, 13)
Reported as:
Geometric mean · mg/L
Trough Levels of Specific Antibodies to Clinically Relevant Pathogen: Haemophilus Influenzae (HIB)
mg/LEpoch 1: IGIV 3-week Interval (Week 1)Epoch 1: IGIV 4-week Interval (Week 1)Epoch 2: IGSC, 20% Weekly (Week 1)Epoch 2: IGSC, 20% Weekly (EOS [Week 24]/ET)Epoch 3: IGSC, 20% Biweekly (Week 1)Epoch 3: IGSC, 20% Biweekly (Week 13)
Trough Levels of Specific Antibodies to Clinically Relevant Pathogen: Haemophilus Influenzae (HIB)1.58 (0.568 to 4.38)1.55 (1.11 to 2.18)2.50 (1.95 to 3.20)1.77 (1.07 to 2.91)2.04 (1.74 to 2.39)1.73 (1.46 to 2.04)
SecondaryHealth Related Quality of Life: Treatment Preference

Treatment preference questionnaire is a self-administered questionnaire developed to assess participants' preference towards the administration of new IGSC therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment. The questionnaire included following categories: Where do you prefer to receive your immunoglobulin therapy, The frequency of administration, as pre-specified in protocol, data is reported as per age (2-13 years and \>=14 years).

Time frame:
Up to approximately 1.5 years
Reported as:
Count of participants · Participants
Health Related Quality of Life: Treatment Preference
ParticipantsIGSC: Epoch 2: 2-13 YearsIGSC: Epoch 2: >=14 YearsIGSC: Epoch 3: 2-13 YearsIGSC: Epoch 3: >=14 Years
Where do you Prefer to Receive Your Immunoglobulin Therapy: At Hospital0001
Where do you Prefer to Receive Your Immunoglobulin Therapy: At Home3114
Where do you Prefer to Receive Your Immunoglobulin Therapy: No Preference1510
The Frequency of Administration: Like Very Much2114
The Frequency of Administration: Like1311
The Frequency of Administration: No Preference1200
The Frequency of Administration: Dislike Very Much0100
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

TEAEs was defined as adverse events (AEs) with onset after date-time of first dose of study drug, or medical conditions present prior to the start of IP but increased in severity or relationship after date-time of first dose of IP. Any TEAE that is recorded by the investigator as "possibly related" or "probably related" to IP was considered as IGSC, 20%-related AE, and any AE recorded as "unlikely related" or "not related" was considered as unrelated AE. AEs included vital signs, clinical laboratory measurements.

Time frame:
From first dose of study drug up to end of study (up to approximately 1.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsEpoch 1: Immune Globulin Intravenous (IGIV)Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)11163
SecondaryNumber of Participants With Tolerability Events Related to the Infusion of Study Drug

An infusion is considered tolerable if the infusion rate was not reduced, or the infusion was not interrupted or stopped, due to TEAE related to study drug (IGIV or IGSC) infusion. A tolerability event is considered to have occurred if an infusion was not tolerable in Epoch 1, Epoch 2 and Epoch 3. Number of participants with tolerability events related to infusion of IP were assessed.

Time frame:
From first dose of study drug up to end of study (up to approximately 1.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Tolerability Events Related to the Infusion of Study Drug
ParticipantsEpoch 1: Immune Globulin Intravenous (IGIV)Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)
Infusions With Infusion Rate Reduced000
Infusions That Were Interrupted010
Infusions That Were Stopped000
Infusions With Infusion Rate Reduced or Interrupted or Stopped010
SecondaryAnnual Rate of Validated Acute Serious Bacterial Infections (ASBI)

The ASBI rate was calculated as the mean number of acute serious bacterial infections per participants per year. Annual rate of validated acute serious bacterial infections per participant was assessed.

Time frame:
From first dose of study drug up to end of study (up to approximately 1.5 years)
Reported as:
Mean · number of infections per year
Annual Rate of Validated Acute Serious Bacterial Infections (ASBI)
number of infections per yearEpoch 1: Immune Globulin Intravenous (IGIV)Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)
Annual Rate of Validated Acute Serious Bacterial Infections (ASBI)0.0 ± 0.000.25 ± 1.0420.0 ± 0.00
SecondaryAnnual Rate of All Infections Per Year

Annual rate is the number of participants reporting any infection per year.

Time frame:
From first dose of study drug up to end of study (up to approximately 1.5 years)
Reported as:
Mean · number of infections per year
Annual Rate of All Infections Per Year
number of infections per yearEpoch 1: Immune Globulin Intravenous (IGIV)Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)
Annual Rate of All Infections Per Year1.65 ± 2.4792.78 ± 3.0740.00 ± 0.000
Statistical analysis
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 1.65 · 95% CI 0.73 to 3.15
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 0.00 · 95% CI 0.00 to 0.00
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 2.48 · 95% CI 1.34 to 4.13
SecondaryNumber of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection

Number of days not able to attend school or work to perform normal daily activities due to illness/infection are standardized per year (365.25 days). The number of days not able to attend school or work to perform normal daily activities due to illness/infection were assessed.

Time frame:
From first dose of study drug up to end of study (up to approximately 1.5 years)
Reported as:
Median · days
Number of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection
daysEpoch 1: Immune Globulin Intravenous (IGIV)Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)
Number of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection0.00 (0.0 to 16.1)0.00 (0.0 to 17.2)4.30 (0.0 to 38.7)
Statistical analysis
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 2.60 · 95% CI 1.02 to 5.30
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 9.82 · 95% CI 2.82 to 23.82
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 2.87 · 95% CI 1.37 to 5.18
SecondaryNumber of Days Participants Were on Antibiotics

Number of days on antibiotics is defined as the number of days those antibiotics were taken as concomitant medications and is standardized to per year (365.25 days). Antibiotics are defined as any medication under anatomical therapeutic chemical Level 2 therapeutic class "ANTIBACTERIALS FOR SYSTEMIC USE". If a participant took multiple antibiotics on a single day, that day is counted for only once. Protocol defined prophylactic antibiotics for viral, fungal or protozoal infections (e.g. trimethoprim/sulfamethoxazole twice a week for pneumocystis) which are not treated by immunoglobulin, were excluded from this analysis.

Time frame:
From first dose of study drug up to end of study (up to approximately 1.5 years)
Reported as:
Median · days
Number of Days Participants Were on Antibiotics
daysEpoch 1: Immune Globulin Intravenous (IGIV)Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)
Number of Days Participants Were on Antibiotics0.00 (0.0 to 31.8)0.00 (0.0 to 34.5)0.00 (0.0 to 21.5)
Statistical analysis
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 4.01 · 95% CI 1.46 to 8.54
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 3.07 · 95% CI 0.37 to 10.74
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 5.87 · 95% CI 2.32 to 11.93
SecondaryNumber of Participants Hospitalized Due to Illness or Infection

Number of participants with hospitalization are standardized to per year (365.25 days). A hospitalization is counted for a specific epoch only if that hospitalization started during that epoch.

Time frame:
From first dose of study drug up to end of study (up to approximately 1.5 years)
Reported as:
Count of participants · Participants
Number of Participants Hospitalized Due to Illness or Infection
ParticipantsEpoch 1: Immune Globulin Intravenous (IGIV)Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)
Number of Participants Hospitalized Due to Illness or Infection000
Statistical analysis
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 0.00 · 95% CI 0.0 to 0.0
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 0.13 · 95% CI 0.03 to 0.35
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 0.00 · 95% CI 0.00 to 0.00
SecondaryLength of Hospital Stay

Length of hospital stay per stay is standardized to per year (365.25 days). A hospitalization is counted for a specific epoch only if that hospitalization started during that epoch.

Time frame:
From first dose of study drug up to end of study (up to approximately 1.5 years)
Reported as:
Median · days
Length of Hospital Stay
daysEpoch 1: Immune Globulin Intravenous (IGIV)Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)
Length of Hospital Stay0.00 (0.0 to 0.0)0.00 (0.0 to 17.4)0.00 (0.0 to 0.0)
Statistical analysis
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 0.00 · 95% CI 0.00 to 0.00
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 1.04 · 95% CI 0.25 to 2.76
SecondaryNumber of Acute Physician Visits Due to Illness/Infection

Number of acute physician visits is standardized to per year (365.25 days).

Time frame:
From first dose of study drug up to end of study (up to approximately 1.5 years)
Reported as:
Mean · number of visits per year
Number of Acute Physician Visits Due to Illness/Infection
number of visits per yearEpoch 1: Immune Globulin Intravenous (IGIV)Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC)Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC)
Number of Acute Physician Visits Due to Illness/Infection1.18 ± 3.0983.30 ± 6.8071.624 ± 8.121
Statistical analysis
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 1.18 · 95% CI 0.38 to 2.68
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 2.35 · 95% CI 0.91 to 4.82
  • Epoch 1: Immune Globulin Intravenous (IGIV) vs Epoch 2: Immune Globulin Subcutaneous 20% Solution (IGSC) vs Epoch 3: Immune Globulin Subcutaneous 20% Solution (IGSC) · Poisson estimate: 0.61 · 95% CI 0.07 to 2.15
SecondaryHealth-related Quality of Life (HRQoL): Pediatric Quality of Life Inventory (PedsQL) Total Scale Score

Peds-QL=generic HR QoL instrument designed specifically for pediatrics has domains as:general health/activities,feelings/emotional,social functioning,school functioning.In this study,2-7 years (parent as observer),8-13 years (participant as observer) for Peds-QL health questionnaire was analyzed.Higher scores=better QOL for all domains.This modular instrument used 5-point scale:0(never) to 4(almost always).Items are reversed scored;linearly transformed to 0-100 scale as follows:0=100,1=75,2=50,3=25,4=0.4 dimensions(physical, emotional, social, \& school functioning) are scored.PEDS-QL Total Scale Score has 0-100 scale,higher scores=better HRQoL.

Time frame:
Baseline up to end of study (approximately 1.5 years)
Reported as:
Mean · score on a scale
Health-related Quality of Life (HRQoL): Pediatric Quality of Life Inventory (PedsQL) Total Scale Score
score on a scaleAge 2-7 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg]Age 8-13 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg]
IGIV: Epoch 1: Baseline (Week 1)88.04 ± 13.83587.23 ± 11.820
IGSC: Epoch 2: Change from Baseline (Week 1)9.78 ± 15.372-6.79 ± 9.977
IGSC: Epoch 3: Change from Baseline (Week 1)14.13 ± NA20.65 ± NA
IGSC: Epoch 3: Change from Baseline (EOS/ET])3.26 ± 7.6864.08 ± 16.374
SecondaryEuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Total Scale Score

EQ-5D-3L health questionnaire=participant answered questionnaire scoring 5 dimensions -mobility,self-care,usual activities, pain/discomfort and anxiety/depression. n this study, 2-11 years (parent as observer),12 years and older (participant as observer) for EQ-5D-3L health questionnaire was analyzed.Health state index score range from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.EQ visual analogue scale range from 0 to 100, where higher scores indicate better health status.Data is reported as per age groups (2-11 years and \>=12 years).

Time frame:
Baseline up to end of the study (approximately 1.5 years)
Reported as:
Mean · score on a scale
EuroQoL (Quality of Life)-5 Dimensions 3 Levels (EQ-5D-3L) Total Scale Score
score on a scaleAge 2-11 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg]Age >=12 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg]
IGIV: Epoch 1: Baseline (Week 1): Health State Index Score0.8080 ± 0.046190.8217 ± 0.04544
IGIV: Epoch 1: Baseline (Week 1): EQ Visual Analogue Scale87.5 ± 15.5577.1 ± 22.16
IGSC: Epoch 2: Change from Baseline (Week 1): Health State Index Score-0.0270 ± 0.122750.0016 ± 0.03318
IGSC: Epoch 2: Change from Baseline (Week 1): EQ Visual Analogue Scale-5.0 ± 5.004.2 ± 17.15
IGSC: Epoch 3: Change from Baseline (Week 1): Health State Index Score0.0000 ± NA0.0133 ± 0.03266
IGSC:Epoch 3: Change from Baseline (Week 1): EQ Visual Analogue Scale0.0 ± NA-1.3 ± 12.39
IGSC: Epoch 3: Change from Baseline (EOS/ET): Health State Index Score0.0400 ± 0.046190.0229 ± 0.04566
IGSC: Epoch 3: Change from Baseline (EOS/ET): EQ Visual Analogue Scale1.3 ± 6.296.9 ± 13.21
SecondaryHealth-related Quality of Life (HRQoL): Short Form-36 Health Survey (SF-36) Score

SF-36=generic quality-of-life instrument that has been widely used to assess HRQL of participants.In this study, 14 years and older (participant as observer) for SF-36 health questionnaire was analyzed. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases.SF-36=36 items aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100.Higher scores=better HRQL. As pre-specified in protocol data is reported for participants with age group of 14 years or older.

Time frame:
Baseline up to end of the study (approximately 1.5 years)
Reported as:
Mean · score on a scale
Health-related Quality of Life (HRQoL): Short Form-36 Health Survey (SF-36) Score
score on a scaleAge 14 Years and Above: IGIV 200 to 600 mg/kg + IGSC (20%) 50 to 200 mg/kg and 100 to 400 mg/kg
IGIV: Epoch 1: Baseline (Week 1): Physical Component Summary Score50.21 ± 7.282
IGIV: Epoch 1: Baseline (Week 1): Mental Component Summary Score50.59 ± 8.114
IGSC: Epoch 2: Change from Baseline (Week 1): Physical Component Summary Score0.10 ± 7.142
IGSC: Epoch 2: Change from Baseline (Week 1): Mental Component Summary Score-0.30 ± 2.294
IGSC: Epoch 3: Change from Baseline (Week 1): Physical Component Summary Score1.81 ± 8.189
IGSC: Epoch 3: Change from Baseline (Week 1): Mental Component Summary Score3.60 ± 5.352
IGSC: Epoch 3: Change from Baseline (EOS/ET): Physical Component Summary Score0.23 ± 4.649
IGSC: Epoch 3: Change from Baseline (EOS/ET): Mental Component Summary Score4.32 ± 8.185
SecondaryHealth Related Quality of Life: Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) Score

TSQM=is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. In this study, 2-12 years (parent as observer), 13 years and older (participant as observer) for TSQM health questionnaire will be analyzed. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain. As pre-specified in protocol, data is reported as per age group (2-12 years and \>=13 years).

Time frame:
Baseline up to end of the study (approximately 1.5 years)
Reported as:
Mean · score on a scale
Health Related Quality of Life: Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) Score
score on a scaleAge 2-12 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg]Age >=13 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg]
IGIV: Epoch 1: Baseline (Week 1): Effectiveness69.44 ± 14.38075.25 ± 18.817
IGIV: Epoch 1: Baseline (Week 1): Convenience62.96 ± 13.90765.66 ± 23.016
IGIV: Epoch 1: Baseline (Week 1): Global Satisfaction75.00 ± 17.92874.68 ± 18.173
IGSC: Epoch 2: Change from Baseline (Week 1): Effectiveness2.22 ± 9.296-1.52 ± 10.568
IGSC: Epoch 2: Change from Baseline (Week 1): Convenience3.33 ± 16.9425.05 ± 13.484
IGSC: Epoch 2: Change from Baseline (Week 1): Global Satisfaction-2.86 ± 10.8331.30 ± 10.507
IGSC: Epoch 3: Change from Baseline (Week 1): Effectiveness2.78 ± 3.928-10.00 ± 52.673
IGSC: Epoch 3: Change from Baseline (Week 1): Convenience13.89 ± 19.64215.56 ± 12.669
IGSC: Epoch 3: Change from Baseline (Week 1): Global Satisfaction-7.14 ± 10.024.29 ± 29.709
IGSC: Epoch 3: Change from Baseline (EOS/ET): Effectiveness9.26 ± 10.9246.57 ± 18.892
IGSC: Epoch 3: Change from Baseline (EOS/ET): Convenience5.56 ± 22.2229.09 ± 23.210
IGSC: Epoch 3: Change from Baseline (EOS/ET): Global Satisfaction7.14 ± 23.9053.90 ± 23.768
SecondaryHealth Related Quality of Life: Treatment Satisfaction Questionnaire for Life Quality Index (LQI) Score

LQI=self-administered questionnaire developed specifically for participants/legal guardians involved in IGIV treatments.2-13 years (parent as observer),14 years and older (participant as observer) for LQI health questionnaire was analyzed.LQI=15-items, divided into 4 domains: treatment interferences(TI)\[6 items\],therapy-related problems(TRP)\[4 items\],therapy setting(TS)\[3 items\];treatment costs(TC)\[2 items\].Items are rated on a 7-point Likert-type scale ranging from 1:"Extremely bad" to 7:"Extremely good".Total scores=0 to 100,higher scores=highest possible satisfaction with factors such as independence,therapy convenience,social/school/work activities;health and travel costs.As pre-specified in protocol, data is reported as per age (2-13 years and \>=14 years).All-Treated Set included all enrolled participants of age group '2-13 years' and '\>=14 years' who received at least 1 dose of study drug (IGIV or IGSC).'n'=Number analysed are participants with data available for analysis.

Time frame:
Baseline up to end of the study (approximately 1.5 years)
Reported as:
Mean · score on a scale
Health Related Quality of Life: Treatment Satisfaction Questionnaire for Life Quality Index (LQI) Score
score on a scaleAge 2-13 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg]Age >=14 Years: Epoch 1[IGIV 200-600 mg/kg]+Epoch 2 [IGSC 50-100 mg/kg]+Epoch 3 [IGSC 100-400 mg/kg]
IGIV: Epoch 1: Baseline (Week 1): Factor 1 Treatment Interference81.48 ± 14.87377.02 ± 17.963
IGIV: Epoch 1: Baseline (Week 1): Factor 2 Therapy-Related Problems81.94 ± 15.51679.17 ± 15.811
IGIV: Epoch 1: Baseline (Week 1): Factor 3 Therapy Setting77.78 ± 20.48874.75 ± 23.748
IGIV: Epoch 1: Baseline (Week 1): Factor 4 Treatment Costs65.28 ± 24.39153.79 ± 21.847
IGSC: Epoch 2: Change from Baseline (Week 1): Factor 1 Treatment Interference-8.33 ± 21.445-2.53 ± 14.351
IGSC: Epoch 2: Change from Baseline (Week 1): Factor 2 Therapy-Related Problems2.78 ± 9.742-1.52 ± 15.841
IGSC: Epoch 2: Change from Baseline (Week 1): Factor 3 Therapy Setting-6.48 ± 30.1060.51 ± 11.773
IGSC: Epoch 2: Change from Baseline (Week 1): Factor 4 Treatment Costs-9.72 ± 22.6180.76 ± 31.282
IGSC: Epoch 3: Change from Baseline (Week 1): Factor 1 Treatment Interference4.17 ± 1.9643.33 ± 4.120
IGSC: Epoch 3: Change from Baseline (Week 1): Factor 2 Therapy-Related Problems-14.58 ± 14.7311.67 ± 14.613
IGSC: Epoch 3: Change from Baseline (Week 1): Factor 3 Therapy Setting19.44 ± 3.92812.22 ± 16.387
IGSC: Epoch 3: Change from Baseline (Week 1): Factor 4 Treatment Costs0.00 ± 0.00018.33 ± 40.139
IGSC: Epoch 3: Change from Baseline (EOS/ET): Factor 1 Treatment Interference-2.78 ± 13.494-0.25 ± 13.046
IGSC: Epoch 3: Change from Baseline (EOS/ET): Factor 2 Therapy-Related Problems-1.39 ± 9.0011.14 ± 9.334
IGSC: Epoch 3: Change from Baseline (EOS/ET): Factor 3 Therapy Setting2.78 ± 16.0054.55 ± 16.067
IGSC: Epoch 3: Change from Baseline (EOS/ET): Factor 4 Treatment Costs4.17 ± 16.67214.39 ± 26.898

Adverse events

Collected over From first dose of study drug up to end of study (up to approximately 1.5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoch 1: IGIV 200-600 mg/kg0/17 (0%)0/17 (0%)11/17 (64.7%)
Epoch 2: IGSC (20%) 50-200 mg/kg0/17 (0%)0/17 (0%)16/17 (94.1%)
Epoch 3: IGSC (20%) 100-400 mg/kg0/7 (0%)0/7 (0%)3/7 (42.9%)
Most frequent other events
Showing 10 of 68
Most frequent other events
EventEpoch 1: IGIV 200-600 mg/kgEpoch 2: IGSC (20%) 50-200 mg/kgEpoch 3: IGSC (20%) 100-400 mg/kg
StomatitisGastrointestinal disorders3/171/170/7
Injection site swellingGeneral disorders0/173/171/7
Injection site erythemaGeneral disorders0/173/171/7
HeadacheNervous system disorders3/173/171/7
Vaccination complicationInjury, poisoning and procedural complications0/171/171/7
Injection site painGeneral disorders0/172/170/7
Vaccination site painGeneral disorders0/172/170/7
NasopharyngitisInfections and infestations2/171/170/7
ConjunctivitisInfections and infestations1/172/170/7
GastroenteritisInfections and infestations0/172/170/7

Baseline characteristics

All-Treated Set included all enrolled participants who received at least 1 dose of study drug (IGIV or IGSC).

Age, Continuous
Age, Continuous(years)IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg
Mean31.0 ± 21.13
Sex: Female, Male
Sex: Female, Male(Participants)IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg
Female7
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg
Hispanic or Latino0
Not Hispanic or Latino17
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg
American Indian or Alaska Native0
Asian17
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Weight
Weight(kilogram (kg))IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg
Mean48.16 ± 18.120
Height
Height(centimeter (cm))IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg
Mean152.15 ± 20.076
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)IGIV 200 to 600 mg/kg + IGSC [50 to 200 and 100 to 400] mg/kg
Mean19.88 ± 3.242
08

Study locations

8 sites
  • Nagoya University Hospital
    Nagoya-shi, Aichi 466-8560, Japan
  • Kyushu University Hospital
    Fukuoka-shi, Fukuoka 812-8582, Japan
  • Kurume University Hospital
    Kurume-shi, Fukuoka 830-0011, Japan
  • Gifu University Hospital
    Gifu-shi, Gifu 501-1194, Japan
  • Hiroshima University Hospital
    Hiroshima-shi, Hiroshima 734-8551, Japan
  • Kanazawa University Hospital
    Kanazawa-shi, Ishikawa 920-8641, Japan
  • National Defense Medical College Hospital
    Tokorozawa-shi, Saitama 359-8513, Japan
  • Tokyo Medical Dental University Hospital
    Bunkyo-ku, Tokyo 113-8519, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Dec 2021, 16 months.

Results were first posted in Mar 2024, 2 years 3 months after primary completion.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2020
First posted
Apr 15, 2020
StartActual
Aug 11, 2020
Primary completionActual
Dec 22, 2021
CompletionActual
Dec 22, 2021
Results first posted
Mar 22, 2024
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04346108
Responsible party
Sponsor
First posted
Apr 15, 2020
Start date
Aug 11, 2020
Primary completion
Dec 22, 2021
Completion
Dec 22, 2021
Results posted
Mar 22, 2024
Last update
Mar 22, 2024

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immunoglobulins, Intravenous · Immunoglobulins · Solutions

Start the discussion